Barely Significant
← all excerpts

Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study.

Nat Commun · 2026 · PMC13153414 · PMID 41839869

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

showed a trendp = 0.05actually significant
3c ), and immune scores showed a trend and modest correlation with PFS (Spearman ρ = 0.35, p = 0.05; Fig. 3d ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.